Mentari Therapeutics, Inc. (MTRI) Revenue, Earnings & Financial Statements
$19.87OTC: MTRIMarket Cap $10.92M
Data as of Nov 16, 2026 (intraday, delayed) · Statements through the quarter ended Sep 2026 · Source: Financial Modeling Prep (methodology)
Mentari Therapeutics, Inc. most recently reported annual revenue of $5.0M, a net loss of $13.0M. Revenue grew at an average annual rate of 25.7% over the last 4 fiscal years. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.
Mentari Therapeutics, Inc.: Revenue rose from $2.0M in 2021 to $5.0M in 2025, a change of +150.0% over 4 years; net profit was positive in 0 of 7 reported years; operating margin moved from -536.0% to -192.0%, a shift of +344.0 percentage points; the most recent year shows a net loss of $13.0M.
Income Statement — 7 Years (USD millions)
Metric
2020
2021
2022
2023
2024
2025
2026
Revenue
—
$2.0M
$1.0M
$4.0M
$5.0M
$5.0M
—
Operating Expenses
$9.0M
$12.0M
$20.0M
$12.0M
$9.0M
$8.0M
$12.0M
Operating Profit
—
−$10.0M
−$19.0M
−$8.0M
—
—
—
Operating Margin
—
-536.0%
-1707.0%
-192.0%
—
—
—
Other Income
$0
$0
−$1.0M
$0
$1.0M
$1.0M
$1.0M
Interest
$0
$0
$0
$0
$0
$0
$0
Depreciation
$0
$0
$0
$0
$0
$0
$0
Profit Before Tax
—
−$10.0M
−$19.0M
−$8.0M
−$8.0M
−$9.0M
−$11.0M
Tax rate (%)
—
—
0.0%
0.0%
0.0%
0.0%
0.0%
Net Profit
−$9.0M
−$10.0M
−$19.0M
−$8.0M
−$8.0M
−$8.0M
−$13.0M
EPS
−$1.71
−$37.96
−$33.17
−$3.25
−$20.14
−$8.36
−$3.12
Quarterly Results — Last 12 Quarters (USD millions)
Metric
Sep '23
Dec '23
Mar '24
Jun '24
Sep '24
Dec '24
Mar '25
Jun '25
Sep '25
Dec '25
Mar '26
Sep '26
Revenue
$1.0M
$1.0M
$1.0M
$1.0M
$1.0M
$1.0M
$1.0M
—
$1.0M
$1.0M
—
—
Operating Expenses
$3.0M
—
—
—
—
—
—
—
—
—
—
—
Operating Profit
−$3.0M
—
—
—
—
—
—
—
—
—
—
—
Operating Margin
-281.0%
—
—
—
—
—
—
—
—
—
—
—
Interest
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
Profit Before Tax
−$3.0M
−$1.0M
−$2.0M
−$2.0M
−$2.0M
−$3.0M
−$2.0M
−$2.0M
−$2.0M
−$2.0M
−$3.0M
−$2.0M
Tax rate (%)
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Net Profit
−$3.0M
−$1.0M
−$2.0M
−$5.0M
−$2.0M
−$3.0M
−$2.0M
−$6.0M
−$2.0M
−$2.0M
−$3.0M
−$2.0M
EPS
−$15.24
−$3.71
−$3.58
−$3.66
−$2.71
−$3.64
−$1.94
−$0.43
−$0.44
−$0.51
−$0.73
−$0.42
Over the 8 years reported for Mentari Therapeutics, Inc., cash stood at $11.0M in the latest year, shareholders' equity was $130.0M, current assets covered current liabilities 1.50 times.
Balance Sheet — 8 Years (USD millions)
Metric
2019
2020
2021
2022
2023
2024
2025
2026
Total Assets
—
$8.0M
$10.0M
$13.0M
$14.0M
$12.0M
$16.0M
$3.0M
Current Assets
—
$6.0M
$8.0M
$10.0M
$11.0M
$9.0M
$13.0M
$3.0M
Cash
$10.0M
$6.0M
$7.0M
$6.0M
$9.0M
$7.0M
$11.0M
$11.0M
Inventory
—
—
—
$2.0M
$2.0M
$1.0M
$1.0M
$1.0M
Receivables
—
$0
$0
$0
$0
$0
$0
$0
Fixed Assets
—
$0
$0
$1.0M
$1.0M
$1.0M
$1.0M
$0
Capital Work in Progress
$0
$0
$0
$0
$0
$0
$0
$0
Investments
—
$0
$0
$0
$0
$0
$0
$0
Other Assets
—
$1.0M
$0
$0
$0
$0
$0
$0
Total Liabilities
—
$2.0M
$2.0M
$4.0M
$2.0M
$3.0M
$2.0M
$2.0M
Current Liabilities
—
$2.0M
$2.0M
$3.0M
$2.0M
$2.0M
$2.0M
$2.0M
Other Liabilities
—
$2.0M
$2.0M
$4.0M
$2.0M
$3.0M
$2.0M
$2.0M
Equity
—
$71.0M
$82.0M
$102.0M
$113.0M
$119.0M
$127.0M
$130.0M
Reserves
$14.0M
$6.0M
$7.0M
$9.0M
$12.0M
$9.0M
$13.0M
$1.0M
For Mentari Therapeutics, Inc., operating cash flow was positive in 0 of 7 reported years; free cash flow in the latest year was negative at $9.0M; free cash flow was positive in 0 of 7 years.
Cash Flow Statement — 7 Years (USD millions)
Metric
2020
2021
2022
2023
2024
2025
2026
Operating Cash Flow
−$7.0M
−$10.0M
−$16.0M
−$7.0M
−$7.0M
−$8.0M
−$9.0M
Investing Cash Flow
$4.0M
$0
−$1.0M
−$1.0M
$0
—
—
Financing Cash Flow
$0
$11.0M
$15.0M
$11.0M
$5.0M
$12.0M
$0
Net Cash Flow
−$4.0M
$1.0M
−$1.0M
$3.0M
−$2.0M
$4.0M
−$9.0M
Free Cash Flow
−$7.0M
−$10.0M
−$16.0M
−$7.0M
−$7.0M
−$8.0M
−$9.0M
Valuation & Return Ratios
Metric
Value
PEG Ratio
—
EV / EBITDA
—
FCF Yield
-195.51%
Quick Ratio
1.00
Interest Coverage
—
Return 1Y
2.76%
Return 3Y
-75.91%
Return 5Y
-99.78%
Mentari Therapeutics, Inc. (MTRI) financials — frequently asked questions
What is Mentari Therapeutics, Inc.'s annual revenue?
Mentari Therapeutics, Inc. (MTRI) reported annual revenue of $5.0M in its most recent fiscal year.
What is Mentari Therapeutics, Inc.'s net profit?
Mentari Therapeutics, Inc. (MTRI) reported a net loss of $13.0M in its most recent fiscal year.